[go: up one dir, main page]

MXPA05006781A - Compuestos para la normalizacion del ciclo de dormir / despertar. - Google Patents

Compuestos para la normalizacion del ciclo de dormir / despertar.

Info

Publication number
MXPA05006781A
MXPA05006781A MXPA05006781A MXPA05006781A MXPA05006781A MX PA05006781 A MXPA05006781 A MX PA05006781A MX PA05006781 A MXPA05006781 A MX PA05006781A MX PA05006781 A MXPA05006781 A MX PA05006781A MX PA05006781 A MXPA05006781 A MX PA05006781A
Authority
MX
Mexico
Prior art keywords
sleep
compound
containing compound
adenosine
wake cycle
Prior art date
Application number
MXPA05006781A
Other languages
English (en)
Inventor
F Renshaw Perry
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Publication of MXPA05006781A publication Critical patent/MXPA05006781A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion provee metodos para normalizar el ciclo de dormir/despertar de un mamifero administrando una cantidad terapeuticamente efectiva de un compuesto que contiene citosina o que contiene citidina , un compuesto que contiene uridina, un compuesto que contiene creatina, un compuesto que contiene adenosina o que eleva la adenosina. Como tales, los metodos descritos en la presente pueden incrementar la sensacion de estar despierto, reducir el cansancio o la fatiga durante el dia, y mejorar la calidad del sueno. Los metodos de la invencion pueden tambien ser usados en el tratamiento de desordenes del sueno, tales como insomnio, apnea del sueno, movimientos periodicos de los miembros, sindrome de la pierna inquieta, narcolepsia, y somnolencia problematica, o para incrementar la funcion cognoscitiva en individuos privados del sueno. La citicolina es un compuesto ejemplar par uso en los metodos descritos en la presente.
MXPA05006781A 2002-12-20 2003-12-17 Compuestos para la normalizacion del ciclo de dormir / despertar. MXPA05006781A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43545702P 2002-12-20 2002-12-20
PCT/US2003/040450 WO2004058160A2 (en) 2002-12-20 2003-12-17 Compounds for the normalization of the sleep/wake cycle

Publications (1)

Publication Number Publication Date
MXPA05006781A true MXPA05006781A (es) 2005-09-30

Family

ID=32682243

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006781A MXPA05006781A (es) 2002-12-20 2003-12-17 Compuestos para la normalizacion del ciclo de dormir / despertar.

Country Status (12)

Country Link
US (1) US20040176316A1 (es)
EP (1) EP1589979A4 (es)
JP (2) JP4717444B2 (es)
CN (1) CN100563660C (es)
AU (1) AU2003299715A1 (es)
BR (1) BR0317586A (es)
CA (1) CA2508995A1 (es)
MX (1) MXPA05006781A (es)
NO (1) NO20052987L (es)
RU (1) RU2366428C2 (es)
UA (1) UA88869C2 (es)
WO (1) WO2004058160A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
JP4667041B2 (ja) * 2002-11-08 2011-04-06 ザ マクレーン ホスピタル コーポレーション タバコ依存症および離脱症状の治療用化合物
WO2005086619A2 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
EP1765075A4 (en) * 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS
US20090215714A1 (en) * 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
NZ563659A (en) 2005-05-23 2011-05-27 Massachusetts Inst Technology Use of compositions containing omega 3 or 6 fatty acids and either uridine or choline for treating Alzheimer's and other memory disorders
TW200827367A (en) * 2006-10-26 2008-07-01 Kyowa Hakko Kogyo Kk A therapeutic agent for irritable bowel syndrome
PT2214521T (pt) * 2007-11-16 2019-03-29 Int Ip Holdings Llc Composição energética comestível com baixo teor de cafeína
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
JP5426918B2 (ja) * 2009-04-20 2014-02-26 株式会社 伊藤園 ウリジンを含有する抗疲労剤又は体力向上剤
JP2011032232A (ja) * 2009-08-04 2011-02-17 Ito En Ltd 興奮抑制用又は鎮静用組成物及びこれを含む飲食品
JP5989319B2 (ja) 2011-10-06 2016-09-07 ライオン株式会社 睡眠の質改善剤
CN104334193A (zh) * 2012-06-04 2015-02-04 辉瑞大药厂 生长激素释放肽受体反向激动剂或拮抗剂用于治疗睡眠障碍的用途
KR102245628B1 (ko) * 2013-04-05 2021-04-28 라이온 가부시키가이샤 내복 조성물
EP3056096B1 (de) * 2015-02-05 2019-07-24 Smart Sleep GmbH Verwendung eines Nahrungsergänzungsmittels enthaltend Kreatin zur Reduktion des natürlichen Schlafbedarfs oder zur schnelleren Anpassung der zirkadianen Rhythmik an neue Zeitzonen
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4115576A (en) * 1974-04-02 1978-09-19 Penn Nathar W Compositions and method of employing the same for inhibiting alcohol intoxication
US4027017A (en) * 1974-07-16 1977-05-31 Chugai Seiyaku Kabushiki Kaisha Method of treating alcoholism
IT1200589B (it) * 1985-02-14 1989-01-27 Gibipharma Spa Derivati naturali attivita farmagologica
JPS63208524A (ja) * 1987-02-25 1988-08-30 Nippon Oil & Fats Co Ltd 睡眠リズム改善剤
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5635486A (en) * 1990-05-11 1997-06-03 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Ophthalmic composition comprising a sleep adjusting substance
CA2109585C (en) * 1991-05-29 2000-02-15 David S. Garvey Isoxazole and isothiazole compounds that enhance cognitive function
US5704361A (en) * 1991-11-08 1998-01-06 Mayo Foundation For Medical Education And Research Volumetric image ultrasound transducer underfluid catheter system
GB9200293D0 (en) * 1992-01-08 1992-02-26 Wyeth John & Brother Ltd Piperazine derivatives
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
ES2244968T3 (es) * 1995-03-06 2005-12-16 Interneuron Pharmaceuticals Incorporated Reduccion del volumen de infarto usando citocolina.
US5888532A (en) * 1996-08-16 1999-03-30 Pritsos; Chris A. Treatment of alcoholism and related disorders with (nicotinamide-adenine dinucleotide) phosphate derivatives
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
ES2294850T3 (es) * 1998-07-31 2008-04-01 Massachusetts Institute Of Technology Tratamiento de la enfermedad de alzheimer mediante el aumento de los niveles de citidina in vivo.
DE19929995B4 (de) * 1999-06-30 2004-06-03 Skw Trostberg Ag Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
ES2170649B1 (es) * 2000-03-29 2003-06-16 Ferrer Int Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline

Also Published As

Publication number Publication date
EP1589979A4 (en) 2009-04-01
WO2004058160A3 (en) 2005-03-31
AU2003299715A1 (en) 2004-07-22
CA2508995A1 (en) 2004-07-15
RU2005122934A (ru) 2006-01-20
BR0317586A (pt) 2005-11-22
WO2004058160A2 (en) 2004-07-15
NO20052987L (no) 2005-08-29
UA88869C2 (ru) 2009-12-10
US20040176316A1 (en) 2004-09-09
RU2366428C2 (ru) 2009-09-10
NO20052987D0 (no) 2005-06-17
CN1750833A (zh) 2006-03-22
JP2006513214A (ja) 2006-04-20
AU2003299715A8 (en) 2004-07-22
CN100563660C (zh) 2009-12-02
EP1589979A2 (en) 2005-11-02
JP2011102319A (ja) 2011-05-26
JP4717444B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
MXPA05006781A (es) Compuestos para la normalizacion del ciclo de dormir / despertar.
WO2022069748A3 (en) Wearable device for decreasing the respiratory effort of a sleeping subject
ES2165878T3 (es) Utilizacion del modafinil para el tratamiento de las apneas del sueño y trastornos de ventilacion de origen central.
IL147794A0 (en) Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
MY174080A (en) Use of dpp iv inhibitors
EP1470146A4 (en) ANTIBODIES AGAINST ANTIGEN MUC18
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
UA84402C2 (ru) Применение монооксида углерода для лечения воспаления почек
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
BR0318185A (pt) composição para administração de ferro para o tratamento de sìndrome das pernas inquietas
EP1482959A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
WO2004024088A3 (en) Design of chemokine analogs for the treatment of human diseases
DE602005026276D1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
PT1261333E (pt) Utilizacao de topiramato para o tratamento e diagnostico de transtorno do sono relacionado com a respiracao e meios para realizar o metodo e o diagnostico
NO20002218D0 (no) Anvendelse av mirtazepin for behandling av søvnapne
SG146451A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
Matheson et al. REM sleep behavior disorder: a dopaminergic deficiency disorder?
MX2023010626A (es) Anticuerpos anti-amiloide beta n3pglu y usos de estos.
DE602004025683D1 (de) Therapeutische zubereitung für autoimmune erkrankungen
TW200508206A (en) Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid, and medicament containing them
PL1599211T3 (pl) Zastosowanie izorhamnetyny do leczenia nastrojów i chorób depresyjnych
MX2021016090A (es) Lemborexant para el tratamiento de problemas del sueño.
PL372313A1 (en) Method for producing pseudo islets
EA200601853A1 (ru) Лечение нарушенной дыхательной функции
Evans et al. Is it migraine or cluster?